Year-End Report April 2024 - March 2025
Regulatory
Sales and operating profit growth, significant product acquisition completed, 11 new products, first deal outside Europe and graduation year passed
Media
Here you can take part in regulatory and non-regulatory press releases and presentations.
Read More
Press Releases
Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2024/25
EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2024/25, on Thursday, May 8[th], before stock markets open.
EQL Pharma signs a distribution agreement with a large distributor in the GCC countries for Mellozzan (melatonin)
EQL has entered into an exclusive distribution agreement with Pharmalink for its product Mellozzan (melatonin) for the GCC (Gulf Cooperation Council) region comprising of United Arab Emirates, Saud...